Inventors:
Scott C. Miller - Longmont CO, US
Juan José Marugán Sánchez - Exton PA, US
Kristin D. Haslow - Downingtown PA, US
Jonathan Hall - Snyder NY, US
Assignee:
3-Dimensional Pharmaceuticals, Inc. - Exton PA
International Classification:
A61K031/505, A61K031/44, A61K031/47, A61K031/40, A61P009/00, C07D239/02, C07D491/00, C07D498/00, C07D215/00, C07D401/00
US Classification:
514424, 514256, 514291, 514302, 514312, 514313, 514314, 514333, 514336, 514337, 514339, 514341, 514343, 514393, 514397, 514411, 514414, 514422, 544335, 546 90, 546115, 546153, 546157, 546159, 546169, 546171, 546173, 546175, 546256, 5462731, 5462741, 5462774, 5462777, 5462781, 5462784, 5483031, 5483147, 548430, 548431, 548467, 548525, 548526, 548527, 548550
Abstract:
The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds having Formula I:
or pharmaceutically acceptable salts thereof; wherein.